Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments.

CEO

Maziar Mike Doustdar

CEOMaziar Mike Doustdar

Employees

68,794

Employees68,794

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1923

Founded1923

Employees

68,794

Employees68,794

NVO Key Statistics

Market cap

217.62B

Market cap217.62B

Price-Earnings ratio

11.27

Price-Earnings ratio11.27

Dividend yield

2.56%

Dividend yield2.56%

Average volume

12.81M

Average volume12.81M

High today

$48.50

High today$48.50

Low today

$47.61

Low today$47.61

Open price

$47.72

Open price$47.72

Volume

9.32M

Volume9.32M

52 Week high

$71.80

52 Week high$71.80

52 Week low

$35.12

52 Week low$35.12

NVO News

Nasdaq 11h

Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?

Novo Nordisk NVO and Viking Therapeutics VKTX are both riding on the powerful growth trend in obesity care, a market expected to expand significantly as demand...

Nasdaq 15h

NVO Crosses Above Average Analyst Target

In recent trading, shares of Novo-Nordisk AS (Symbol: NVO) have crossed above the average analyst 12-month target price of $47.78, changing hands for $48.07/sha...

Simply Wall St 1d

Novo Nordisk Stock In Focus As Medicare Opens A New Wegovy Market

The Medicare Bridge program is set to open the door for millions of seniors to access obesity drugs such as Wegovy from Novo Nordisk and Zepbound from Eli Lilly...

Analyst ratings

54%

of 37 ratings

Buy

37.8%

Hold

54.1%

Sell

8.1%

More NVO News

CNBC 2d

Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet

Key Points Millions of older Americans in Medicare are about to gain access to obesity drugs through Medicare's new Bridge demonstration program for a monthly c...

Simply Wall St 2d

Will Novo Nordisk’s GLP-1 Telehealth Tie-Up Change Hims & Hers Health's Cash-Pay Narrative - simplywall.st

...

Nasdaq 3d

Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly?

Key Points Eli Lilly leads in next‑gen obesity drugs, while Novo Nordisk offers a cheaper, dividend‑paying alternative. Novo’s steady insulin cash flows and n...

TipRanks 4d

Novo Nordisk Tests Cagrilintide in Patients Who Cannot Tolerate GLP-1 Weight-Loss Drugs

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more...

Nasdaq 4d

An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?

Key Points "The field is getting more crowded -- but Lilly is widening its lead,” said RBC analyst Trung Huynh. Until Novo Nordisk gets back to positive growt...

The Motley Fool 5d

The Artificial Intelligence Opportunity Beyond Big Tech: 3 Healthcare Stocks to Watch

Investors looking to capitalize on the rapidly growing artificial intelligence (AI) industry tend to turn toward leading tech corporations. That's understandabl...

Simply Wall St 6d

Novo Nordisk Stock After Recent Pharma Sector Focus Is The Valuation Attractive

If you are wondering whether Novo Nordisk stock is starting to look attractively priced or still carries a premium, the current setup offers plenty of clues in...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.